General Mills (GIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Aug, 2026Executive summary
Focused on the Accelerate strategy to drive sustainable, profitable growth and long-term shareholder returns, emphasizing brand building, innovation, scale, and responsible business practices.
Fiscal 2026 priorities included restoring North America Retail volume growth, accelerating North America Pet segment, and driving efficiencies for reinvestment.
Completed U.S. Yogurt divestiture, integrated Whitebridge Pet Brands, and announced divestitures of Brazil business and Häagen-Dazs shops in China.
Returned $1.8 billion to shareholders via dividends and share repurchases in fiscal 2026.
Fiscal 2026 net sales were $18.4 billion, adjusted operating profit $2.8 billion, and adjusted diluted EPS $3.55, with free cash flow conversion at 85%.
Voting matters and shareholder proposals
Shareholders to vote on election of 12 directors, advisory approval of executive compensation, ratification of KPMG as auditor, amendments to the Certificate of Incorporation for officer exculpation and federal forum provision, and three shareholder proposals.
Board recommends FOR all management proposals and AGAINST all shareholder proposals, including restrictions on blank-check preferred stock, a report on human rights, and pesticide reduction reporting.
Board of directors and corporate governance
Board is majority independent, with 10 of 12 directors independent and diverse in gender and ethnicity.
Board actively oversees strategy, risk, succession planning, and sustainability, with regular evaluations and refreshment.
Five standing committees: Audit, Compensation and Talent, Corporate Governance, Finance, and Public Responsibility, all chaired by independent directors.
Annual director elections by majority vote, proxy access by-law, and right to call special meetings.
Latest events from General Mills
- Net sales fell 3% and adjusted EPS dropped 13%, but full-year guidance was reaffirmed.GIS
Q1 2027 (Q&A) - Flat organic sales, profit declines, and strong cost savings support reaffirmed FY27 outlook.GIS
Q1 2027 Prepared remarks - Q1 momentum, cost savings, and innovation drive optimism for sustainable growth in FY27.GIS
Barclays 19th Annual Global Consumer Conference - Proxy statement details filing status, material types, and fee disclosures.GIS
Proxy filing - Proxy details board elections, pay, auditor, and ESG progress; board opposes all shareholder proposals.GIS
Proxy filing - FY27 targets $750M in cost savings and modest sales growth amid ongoing market headwinds.GIS
Q4 2026 Prepared remarks - Sales and profit fell, but 2025 guidance was reaffirmed and a major yogurt divestiture announced.GIS
Q1 2025 (Q&A) - Flat sales and profit in 2024; modest growth and higher brand investment targeted for 2025.GIS
Q4 2024 (Q&A) - Five years of innovation, portfolio reshaping, and $11B+ returned to shareholders, with near-term caution.GIS
Consumer Analyst Group of New York Conference 2025